Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $804.6 million. The company’s full-year revenue guidance of $3.07 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.96 per share was 16.3% above analysts’ consensus estimates.
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST)
jumped 12.3% in the afternoon session after the company reported strong third-quarter 2025 results that surpassed analyst estimates and raised its full-year financial forecast.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's oil giants sparked a sharp rebound in crude prices and lifted energy shares.
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Thursday to uncover the stocks that are gapping in the S&P500 index.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.
West Pharmaceutical Services (WST) beats Q3 2025 earnings and revenue estimates, raises full-year guidance. The strong results, led by an EPS beat, sent the stock up over 6% pre-market.
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $804.6 million. The company’s full-year revenue guidance of $3.07 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.96 per share was 16.3% above analysts’ consensus estimates.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 8.4% gain for healthcare stocks has fallen short of the S&P 500’s 22.7% rise.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at drug development inputs & services stocks, starting with Medpace (NASDAQ:MEDP).
West Pharmaceutical Services has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 16.3% to $260.31 per share while the index has gained 18.6%.
In a significant shift that has caught the attention of financial markets and online communities alike, Bill Gates, through his investment vehicle Cascade Investment, has made notable adjustments to his extensive portfolio. The most prominent move, widely discussed on platforms like Reddit, involves a substantial increase in his stake in
